Exact Mass: 508.2468
Exact Mass Matches: 508.2468
Found 248 metabolites which its exact mass value is equals to given mass value 508.2468
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Argatroban
Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients with HIT and prevent the formation of thrombi. Parental anticoagulants must be stopped and a baseline activated partial thromboplastin time must be obtained prior to administering argatroban. D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors D006401 - Hematologic Agents > D000925 - Anticoagulants > D000991 - Antithrombins D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors
PD 123319
D057911 - Angiotensin Receptor Antagonists > D057912 - Angiotensin II Type 2 Receptor Blockers D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents
Argatroban
B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AE - Direct thrombin inhibitors D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors D006401 - Hematologic Agents > D000925 - Anticoagulants > D000991 - Antithrombins COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
ID14326
ID14326 is a metabolite of lurasidone. Lurasidone (trade name Latuda) is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 28, 2010 after a review that found that two of the four Phase III clinical trials supported efficacy, while one showed only marginal efficacy and one was not interpretable because of high drop-out rates. (Wikipedia)
1-[[4-(Dimethylamino)-3-methylphenyl]methyl]-5-(2,2-diphenylacetyl)-6,7-dihydro-4H-imidazo[4,5-c]pyridine-6-carboxylic acid
D057911 - Angiotensin Receptor Antagonists > D057912 - Angiotensin II Type 2 Receptor Blockers D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents
(1R,3R)-5-[(2E)-2-[(3As,7aS)-7a-methyl-1-[(Z,2R)-7,7,7-trifluoro-6-hydroxy-6-(trifluoromethyl)hept-4-en-2-yl]-3a,5,6,7-tetrahydro-3H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol
Kushenol M
Kushenol M is a natural product found in Sophora flavescens with data available.
Tanariflavanone A
A hydroxyflavanone with a pyranochromane skeleton that is 3,4,7,8-tetrahydro-2H,6H-pyrano[3,2-g]chromen-6-one substituted by geminal methyl groups at position 2, hydroxy groups at positions 3 and 5 and a phenyl group at position 8 which in turn is substituted by a geranyl group at position 2 and hydroxy groups at positions 3 and 4. Isolated from Macaranga tanarius, it exhibits alleopathic effect.
Petalostemumol
Tanariflavanone C
A tetrahydroxyflavanone that is (2S)-flavanone substituted by hydroxy groups at positions 5,7, 3 and 4, a geranyl group at position 2 and a 2-hydroxy-3-methylbut-3-en-1yl group at position 6. Isolated from Macaranga tanarius, it exhibits radical scavenging activity.
(12R)-12-cinnamoyloxy-3beta,5-dihydroxy-8,14-seco-5beta,17beta-pregn-6-ene-8,14,20-trione|cynaphyllogenin|Cynaphylloside
(-)-(7S,7S,8R,8S,8R)-4,4-dihydroxy-3,3,5-trimethoxy-4,8-oxy-2,7-cyclo-8,8-sesquineolignan-7-ol
A neolignan isolated from the barks of Machilus robusta.
(E)-2,3-dihydro-4-hydroxy-2-(1-hydroxy-1-methylethyl)-7,8-dimethoxy-6-(3,7-dimethyl-2,6-octadienyl)-5H-furo[3,2-b]xanthen-5-one|oliverixanthone
Cys Lys Lys Met
Cys Lys Met Lys
Cys Met Lys Lys
Asp Ile Val Tyr
Asp Ile Tyr Val
Asp Leu Val Tyr
Asp Leu Tyr Val
Asp Val Ile Tyr
Asp Val Leu Tyr
Asp Val Tyr Ile
Asp Val Tyr Leu
Asp Tyr Ile Val
Asp Tyr Leu Val
Asp Tyr Val Ile
Asp Tyr Val Leu
Glu Phe Ile Thr
Glu Phe Leu Thr
Glu Phe Thr Ile
Glu Phe Thr Leu
Glu Ile Phe Thr
Glu Ile Thr Phe
Glu Leu Phe Thr
Glu Leu Thr Phe
Glu Thr Phe Ile
Glu Thr Phe Leu
Glu Thr Ile Phe
Glu Thr Leu Phe
Glu Val Val Tyr
Glu Val Tyr Val
Glu Tyr Val Val
Phe Glu Ile Thr
Phe Glu Leu Thr
Phe Glu Thr Ile
Phe Glu Thr Leu
Phe Ile Glu Thr
Phe Ile Thr Glu
Phe Leu Glu Thr
Phe Leu Thr Glu
Phe Thr Glu Ile
Phe Thr Glu Leu
Phe Thr Ile Glu
Phe Thr Leu Glu
Gly Asn Arg Tyr
Gly Asn Tyr Arg
Gly Arg Asn Tyr
Gly Arg Tyr Asn
Gly Tyr Asn Arg
Gly Tyr Arg Asn
His Pro Gln Gln
His Gln Pro Gln
His Gln Gln Pro
Ile Asp Val Tyr
Ile Asp Tyr Val
Ile Glu Phe Thr
Ile Glu Thr Phe
Ile Phe Glu Thr
Ile Phe Thr Glu
Ile Thr Glu Phe
Ile Thr Phe Glu
Ile Val Asp Tyr
Ile Val Tyr Asp
Ile Tyr Asp Val
Ile Tyr Val Asp
Lys Cys Lys Met
Lys Cys Met Lys
Lys Lys Cys Met
Lys Lys Met Cys
Lys Met Cys Lys
Lys Met Lys Cys
Leu Asp Val Tyr
Leu Asp Tyr Val
Leu Glu Phe Thr
Leu Glu Thr Phe
Leu Phe Glu Thr
Leu Phe Thr Glu
Leu Thr Glu Phe
Leu Thr Phe Glu
Leu Val Asp Tyr
Leu Val Tyr Asp
Leu Tyr Asp Val
Leu Tyr Val Asp
Met Cys Lys Lys
Met Lys Cys Lys
Met Lys Lys Cys
Asn Gly Arg Tyr
Asn Gly Tyr Arg
Asn Arg Gly Tyr
Asn Arg Tyr Gly
Asn Tyr Gly Arg
Asn Tyr Arg Gly
Pro His Gln Gln
Pro Gln His Gln
Pro Gln Gln His
Gln His Pro Gln
Gln His Gln Pro
Gln Pro His Gln
Gln Pro Gln His
Gln Gln His Pro
Gln Gln Pro His
Arg Gly Asn Tyr
Arg Gly Tyr Asn
Arg Asn Gly Tyr
Arg Asn Tyr Gly
Arg Tyr Gly Asn
Arg Tyr Asn Gly
Thr Glu Phe Ile
Thr Glu Phe Leu
Thr Glu Ile Phe
Thr Glu Leu Phe
Thr Phe Glu Ile
Thr Phe Glu Leu
Thr Phe Ile Glu
Thr Phe Leu Glu
Thr Ile Glu Phe
Thr Ile Phe Glu
Thr Leu Glu Phe
Thr Leu Phe Glu
Val Asp Ile Tyr
Val Asp Leu Tyr
Val Asp Tyr Ile
Val Asp Tyr Leu
Val Glu Val Tyr
Val Glu Tyr Val
Val Ile Asp Tyr
Val Ile Tyr Asp
Val Leu Asp Tyr
Val Leu Tyr Asp
Val Val Glu Tyr
Val Val Tyr Glu
Val Tyr Asp Ile
Val Tyr Asp Leu
Val Tyr Glu Val
Val Tyr Ile Asp
Val Tyr Leu Asp
Val Tyr Val Glu
Tyr Asp Ile Val
Tyr Asp Leu Val
Tyr Asp Val Ile
Tyr Asp Val Leu
Tyr Glu Val Val
Tyr Gly Asn Arg
Tyr Gly Arg Asn
Tyr Ile Asp Val
Tyr Ile Val Asp
Tyr Leu Asp Val
Tyr Leu Val Asp
Tyr Asn Gly Arg
Tyr Asn Arg Gly
Tyr Arg Gly Asn
Tyr Arg Asn Gly
Tyr Val Asp Ile
Tyr Val Asp Leu
Tyr Val Glu Val
Tyr Val Ile Asp
Tyr Val Leu Asp
Tyr Val Val Glu
Argatroban Impurity 26
Clocortolone Caproate
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid
5-[(2E)-2-[7a-methyl-1-[(E)-7,7,7-trifluoro-6-hydroxy-6-(trifluoromethyl)hept-4-en-2-yl]-3a,5,6,7-tetrahydro-3H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol
(6S)-1-[4-(dimethylamino)-3-methylbenzyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid
D057911 - Angiotensin Receptor Antagonists > D057912 - Angiotensin II Type 2 Receptor Blockers D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents
N-[(3R,3R,4S,5R)-5-(2-hydroxyethyl)-4-[(4-methoxyphenyl)-dimethylsilyl]-3-methyl-2-oxo-1-prop-2-enyl-5-spiro[indole-3,2-oxolane]yl]acetamide
(1S)-1-[(3-fluorophenyl)-oxomethyl]-1-(hydroxymethyl)-7-methoxy-N-propyl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
cyclohexyl-[(1R)-1-(hydroxymethyl)-7-methoxy-2-(2-thiazolylmethyl)-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanone
(1S)-2-[(4-fluorophenyl)-oxomethyl]-1-(hydroxymethyl)-7-methoxy-N-propan-2-yl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
(1R)-N-(4-fluorophenyl)-1-(hydroxymethyl)-7-methoxy-1-(4-oxanylmethyl)-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]carboxamide
(1R)-N-(3-fluorophenyl)-1-(hydroxymethyl)-7-methoxy-1-(4-oxanylmethyl)-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]carboxamide
(1R)-1-[(3-fluorophenyl)-oxomethyl]-1-(hydroxymethyl)-7-methoxy-N-propyl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
cyclohexyl-[(1S)-1-(hydroxymethyl)-7-methoxy-2-(2-thiazolylmethyl)-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanone
(1R)-2-[(4-fluorophenyl)-oxomethyl]-1-(hydroxymethyl)-7-methoxy-N-propan-2-yl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-3-(8-hydroxy-3,7-dimethylocta-2,6-dien-1-yl)-6-(3-methylbut-2-en-1-yl)-3,4-dihydro-2H-1-benzopyran-4-one
1-[[4-(Dimethylamino)-3-methylphenyl]methyl]-5-(2,2-diphenylacetyl)-6,7-dihydro-4H-imidazo[4,5-c]pyridine-6-carboxylic acid
D057911 - Angiotensin Receptor Antagonists > D057912 - Angiotensin II Type 2 Receptor Blockers D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents
5-(acetyloxy)-1-(furan-3-yl)-3b,6,6,9a,11a-pentamethyl-2,7-dioxo-1h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-4-yl acetate
(1r,3br,4s,5r,5ar,9as,9br,11as)-4-(acetyloxy)-1-(furan-3-yl)-3b,6,6,9a,11a-pentamethyl-2,7-dioxo-1h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-5-yl acetate
{3-hydroxy-4-[(2s)-2-hydroxy-6-methylheptan-2-yl]phenyl}methyl 2-hydroxy-4-(3-hydroxy-5-methylphenoxy)-6-methylbenzoate
2-[3,4-dihydroxy-2,6-bis(3-methylbut-2-en-1-yl)phenyl]-3,5,7-trihydroxy-8-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
[(5ar,7ar,8r,9s,11as,11br)-9-(acetyloxy)-5a,8,11a-trimethyl-1-oxo-3-phenyl-6,7,7a,9,10,11,11b,12-octahydro-2,5-dioxatetraphen-8-yl]methyl acetate
(2s)-2-[(2s)-2-[(1-hydroxyethylidene)amino]-n-methyl-3-phenylpropanamido]-n-[(1z)-2-(1h-indol-3-yl)ethenyl]-3-phenylpropanimidic acid
anhydrohirundigenin monothevetoside
{"Ingredient_id": "HBIN016162","Ingredient_name": "anhydrohirundigenin monothevetoside","Alias": "NA","Ingredient_formula": "C30H29FN6O","Ingredient_Smile": "CCNCC(=CC(=CC)C1=NC2=C(C=C1)NNC2=C3C=C4C(=N3)C=CN=C4C5=CC(=CC(=C5)F)OC)C=C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1272","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}